Difference between revisions of "ALK inhibitors"
Jump to navigation
Jump to search
| Line 10: | Line 10: | ||
*[[Inflammatory myofibroblastic tumour]]. | *[[Inflammatory myofibroblastic tumour]]. | ||
*[[ALK positive lung cancer]]. | *[[ALK positive lung cancer]]. | ||
*[[ALK translocation renal cell carcinoma]]. | |||
==References== | ==References== | ||
Revision as of 14:10, 4 April 2019
ALK inhibitors are a group of drugs that act on tumours with ALK rearrangements.
- Alectinib.[1][2]
- Crizotinib.
- Ceritinib.
- Brigatinib.
- Lorlatinib.
See also
- Inflammatory myofibroblastic tumour.
- ALK positive lung cancer.
- ALK translocation renal cell carcinoma.
References
- ↑ Honda, K.; Kadowaki, S.; Kato, K.; Hanai, N.; Hasegawa, Y.; Yatabe, Y.; Muro, K. (Feb 2019). "Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.". Invest New Drugs. doi:10.1007/s10637-019-00742-2. PMID 30790150.
- ↑ Pal, SK.; Bergerot, P.; Dizman, N.; Bergerot, C.; Adashek, J.; Madison, R.; Chung, JH.; Ali, SM. et al. (07 2018). "Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.". Eur Urol 74 (1): 124-128. doi:10.1016/j.eururo.2018.03.032. PMID 29685646.